Results 11 to 20 of about 2,860,326 (352)

Single-domain antibodies and their formatting to combat viral infections [PDF]

Antibodies, 2018
Since their discovery in the 1990s, single-domain antibodies (VHHs), also known as NanobodiesA (R), have changed the landscape of affinity reagents. The outstanding solubility, stability, and specificity of VHHs, as well as their small size, ease of ...
Ballegeer, Marlies, De Vlieger, Dorien, Rossey, Iebe, Saelens, Xavier, Schepens, Bert   +4 more
core   +3 more sources

Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex [PDF]

Journal of Virology, 2017
Human cytomegalovirus (HCMV) is the leading cause of congenital viral infection, and developing a prophylactic vaccine is of high priority to public health.
Adler, Stuart P., An, Zhiqiang, DePhillips, Pete A., Freed, Daniel C., Fu, Tong-Ming, Ha, Sha, Hamm, Melissa, Li, Fengsheng, Loughney, John W., McLellan, Jason S., McVoy, Michael A., Nickle, David C., Rustandi, Richard R., Tang, Aimin, Troutman, Matthew C., Vlasak, Josef, Wang, Dai, Wang, I-Ming, Zhang, Ningyan, Zhu, Hua   +19 more
core   +4 more sources

Antibodies to combat viral infections: development strategies and progress

Nature reviews. Drug discovery, 2022
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for viral infections owing to characteristics such as their high specificity and their ability to enhance immune responses.
G. Pantaleo, B. Correia, C. Fenwick, Victor S. Joo, L. Perez   +4 more
semanticscholar   +1 more source

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Science, 2021
Mapping antibody escape in SARS-CoV-2 Several antibodies are in use or under development as therapies to treat COVID-19. As new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge, it is important to predict whether they will ...
Tyler N. Starr, Allison J. Greaney, A. Addetia, William W. Hannon, M. Choudhary, A. Dingens, Jonathan Z. Li, Jesse D. Bloom   +7 more
semanticscholar   +1 more source

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

bioRxiv, 2020
Antibodies are becoming a frontline therapy for SARS-CoV-2, but the risk of viral evolutionary escape remains unclear. Here we map how all mutations to SARS-CoV-2’s receptor-binding domain (RBD) affect binding by the antibodies in Regeneron’s REGN-COV2 ...
Tyler N. Starr, Allison J. Greaney, A. Addetia, William W. Hannon, M. Choudhary, A. Dingens, Jonathan Z. Li, J. Bloom   +7 more
semanticscholar   +1 more source

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Science immunology, 2020
The serum level of RBD-binding antibodies correlates with SARS-CoV-2 neutralization and can be used for population-level surveillance. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first emerged in late 2019 is responsible for a ...
L. Premkumar, Bruno Segovia-Chumbez, R. Jadi, David R. Martinez, R. Raut, A. Markmann, Caleb Cornaby, L. Bartelt, S. Weiss, Yara Park, C. Edwards, E. Weimer, E. Scherer, N. Rouphael, Srilatha Edupuganti, D. Weiskopf, Longping V. Tse, Yixuan J. Hou, D. Margolis, A. Sette, M. Collins, J. Schmitz, R. Baric, A. D. de Silva   +23 more
semanticscholar   +1 more source

Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans

Viruses, 2021
While SARS-CoV-2 specific neutralizing antibodies have been developed for therapeutic purposes, the specific viral triggers that drive the generation of SARS-CoV-2 specific IgG and IgM antibodies remain only partially characterized.
Shuyi Yang, Keith R. Jerome, Alexander L. Greninger, Joshua T. Schiffer, Ashish Goyal   +4 more
doaj   +1 more source

Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection

Nature, 2020
Antibodies against viral pathogens represent promising therapeutic agents for the control of infection, and their antiviral efficacy has been shown to require the coordinated function of both the Fab and Fc domains 1 .
S. Bournazos, D. Corti, H. Virgin, J. Ravetch   +3 more
semanticscholar   +1 more source

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Nature, 2022
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.2.12.1, BA.4 and BA.5 exhibit higher transmissibility than the BA.2 lineage1.
Yunlong Cao, A. Yisimayi, F. Jian, Weiliang Song, T. Xiao, Lei Wang, Shuo Du, Jing Wang, Qian-qian Li, Xiaosu Chen, Yuanling Yu, Peng Wang, Zhiying Zhang, Pulan Liu, R. An, Xiaohua Hao, Yao Wang, Jing Wang, Rui Feng, Haiyan Sun, Li-Jin Zhao, Wen Zhang, Dong Zhao, Jiang Zheng, Lingling Yu, Can Li, Na Zhang, Rui Wang, Xiaowei Niu, Sijie Yang, Xuetao Song, Yangyang Chai, Ye Hu, Yan-mei Shi, Linlin Zheng, Zhiqiang Li, Qingqing Gu, Fei Shao, Weijing Huang, R. Jin, Zhongyang Shen, Youchun Wang, Xiangxi Wang, Junyu Xiao, X. Xie   +44 more
semanticscholar   +1 more source

Mechanisms of hemagglutinin targeted influenza virus neutralization. [PDF]

PLoS ONE, 2013
Human monoclonal antibodies have been identified which neutralize broad spectra of influenza A or B viruses. Here, we dissect the mechanisms by which such antibodies interfere with infectivity.
Boerries Brandenburg, Wouter Koudstaal, Jaap Goudsmit, Vincent Klaren, Chan Tang, Miriam V Bujny, Hans J W M Korse, Ted Kwaks, Jason J Otterstrom, Jarek Juraszek, Antoine M van Oijen, Ronald Vogels, Robert H E Friesen   +12 more
doaj   +1 more source